Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alparis
Zug, Zug, Switzerland
- Ownership
- Private
- Development stage
- Other
01
Overview
Alparis is a Swiss biopharmaceutical company dedicated to the development of novel small molecule therapies for rare metabolic and inflammatory disorders. The company's lead candidate, AP-101, is an oral pharmacological chaperone designed to treat Alpha-1 Antitrypsin Deficiency (AATD). By targeting the misfolded Z-variant of the alpha-1 antitrypsin protein, AP-101 aims to restore proper protein folding, thereby reducing toxic liver accumulation and increasing protective levels in the lungs. Alparis was founded by a team of experienced biotechnology executives and is currently advancing its pipeline through early-stage clinical trials. The company's approach leverages deep expertise in protein folding and small molecule drug discovery to address significant unmet medical needs.
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Alparis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alparis.